Management of Autoimmune Hepatitis
Introduction to Treatment
- The American Association for the Study of Liver Diseases recommends that all patients with active autoimmune hepatitis should receive combination therapy with prednisolone plus azathioprine as first-line treatment, which achieves remission in 80-90% of patients and significantly improves survival 1, 2
First-Line Treatment
- The European Association for the Study of the Liver suggests starting prednisolone 30 mg/day combined with azathioprine 1-2 mg/kg/day, and tapering prednisolone over 4 weeks to a maintenance dose of 10 mg/day, then further reducing to 7.5 mg/day once aminotransferases normalize, and after 3 months taper to 5 mg/day 2, 3
- The American College of Gastroenterology recommends maintaining azathioprine at 1-2 mg/kg/day as a steroid-sparing agent throughout treatment 2
Pre-Treatment Requirements
- The American Gastroenterological Association advises checking thiopurine methyltransferase (TPMT) levels before starting azathioprine to exclude homozygote deficiency 1, 2
- The European Association for the Study of the Liver suggests screening for hepatitis B (HBsAg, anti-HBc, anti-HBs) to identify patients requiring monitoring for reactivation 2
Treatment Monitoring and Goals
- The American Association for the Study of Liver Diseases recommends that complete normalization of both ALT and IgG levels is the therapeutic endpoint, not just improvement 1, 2
- The European Association for the Study of the Liver suggests assessing treatment response at 4-8 weeks after initiation, and monitoring serum aminotransferase levels monthly 3
Alternative First-Line Therapy
- The American College of Gastroenterology recommends using budesonide 3 mg three times daily plus azathioprine (1-2 mg/kg/day) for non-cirrhotic patients at high risk for steroid side effects 6, 2
Management of Treatment Failure or Intolerance
- The European Association for the Study of the Liver suggests increasing azathioprine to 2 mg/kg/day while continuing prednisolone (5-10 mg/day) for patients failing to achieve remission after 2 years on prednisolone plus azathioprine 6
Relapse Management
- The American Association for the Study of Liver Diseases recommends that 50-90% of patients relapse within 12 months of stopping treatment following biochemical and histological remission, and that risk factors for relapse include raised serum ALT or AST at withdrawal, raised serum globulin/IgG, and liver biopsy with any inflammation or portal tract plasma cells 6, 3
Special Populations
- The American College of Gastroenterology advises that azathioprine requires risk-benefit analysis but may be continued if disease control requires it during pregnancy 1, 2
- The European Association for the Study of the Liver recommends using high-dose prednisone for up to 2 weeks, then gradual decrease to maintenance for children with AIH 1
Critical Pitfalls to Avoid
- The American Gastroenterological Association warns that stopping treatment too early can result in 50-90% of patients relapsing within 12 months, and that persistent ALT elevation predicts poor outcomes including progressive fibrosis and liver-related death 2, 6